📈 Jumpstart Signal Watchlist — September 15, 2026

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $56.90 is 4% below 3yr high $59.13 · ⏳ SMA200 $47.94 (current price $56.90 is above) · 💰 Market Cap $14.2B
- EXEL presents a compelling setup with strong technicals and positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 26% (>20%); ROE 47% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 6/20
- 🔔 SMA20/SMA50 bullish crossover
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 7/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×3 ❌×1 ⚪️×1; showing 4 of 5).
✅ Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises — Yahoo Finance.
🤖 Management highlighted rising CABOMETYX market share, a potential roughly $5 billion addressable market for zanzalintinib, and continued share repurchases. These growth and capital-allocation plans are favorable for the stock, although they depend on future clinical and regulatory execution.
✅ Exelixis at Citigroup summit: building a second growth engine — Investing.com.
🤖 Exelixis described continued CABOMETYX commercial gains and plans to develop zanzalintinib into a second growth franchise, supported by multiple pivotal studies and operating-margin expansion potential. Management also acknowledged development risk, tempering the otherwise favorable outlook.
❌ Exelixis (EXEL) Up 13.3% Since Last Earnings Report — Yahoo Finance.
🤖 Exelixis beat second-quarter EPS expectations with adjusted EPS of $0.91, but management lowered 2026 revenue guidance to $2.50-$2.55 billion from $2.525-$2.625 billion. The guidance reduction is a negative catalyst despite the earnings beat.
⚪️ Citizens reiterates Exelixis stock rating on FDA review extension — Investing.com.
🤖 Citizens maintained its Market Outperform rating and $55 price target after the FDA extended its review of zanzalintinib to March 3, 2027. The unchanged rating provides support, while the delayed regulatory decision limits near-term upside visibility.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Match Group operates a portfolio of online dating and relationship apps and websites, including Tinder, Hinge, Match, OkCupid, and Plenty of Fish. Its services are designed to help people make meaningful connections and meet potential partners through digital platforms.
- 🎯 Current $44.40 is 2% below 3yr high $45.26 · ⏳ SMA200 $34.95 (current price $44.40 is above) · 💰 Market Cap $10.2B
- MTCH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 44/60
- 🏦 Low drawdown (11.6% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 43% (>20%); PEG ratio 0.37 (<1.5).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA21 (7.1%)
- 🔔 Strong above EMA50 (11.3%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 69 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Match Group (NASDAQ:MTCH) Reaches New 12-Month High - Here's What Happened — MarketBeat.
🤖 MTCH reached a new 12-month high after its latest quarterly adjusted EPS of $0.70 exceeded the $0.65 consensus estimate. The article also notes revenue declined 1.2% year over year and was slightly below expectations, but the share-price milestone and earnings beat are favorable signals.
✅ Hinge Growth Strategy — Investing.com.
🤖 At Citi's TMT conference, Match said Tinder engagement improved in August and showed early further progress in September following a recommendation-algorithm rollout. Hinge continued to post double-digit user and payer growth, while the company raised its estimated alternative-payment savings to $130 million.
✅ Match Group at Goldman Sachs conference: tinder push aims to revive growth — Investing.com.
🤖 Match outlined a turnaround plan at the Goldman Sachs conference built around product changes, marketing tools, and greater use of AI. The strategy targets a revival in Tinder growth, which is constructive for the company’s core business outlook.
🍭 Bonus (B): 10/10 — Computer Programming & Data Processing (Technology sector)

🏢 What they do: Red Violet, Inc. provides identity intelligence software and data solutions for identity verification, fraud detection and prevention, risk mitigation, investigations, due diligence, customer acquisition, and asset recovery. Its products include idiCORE and FOREWARN.
- 🎯 Current $76.21 is 0% below 3yr high $76.43 · ⏳ SMA200 $53.20 (current price $76.21 is above) · 💰 Market Cap $1.1B
- RDVT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 89% (>20%); Revenue growth 23% (>15%); Low LT D/E 0.00 (<1.0); PEG ratio 0.76 (<1.5).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA50 (10.9%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 60 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ Red Violet (RDVT) Hits New 12-Month High - MarketBeat — MarketBeat.
🤖 The article says RDVT hit a new 52-week high after the company beat second-quarter expectations with EPS of $0.50 versus $0.33 consensus and revenue of $26.72 million versus $25.62 million. That earnings beat and the strong price action are positive for the stock.
✅ Red Violet (RDVT) Turns Record Growth Into Real Profit Gains — Yahoo Finance.
🤖 This piece highlights Red Violet's strong second-quarter 2026 results, including 23% revenue growth to $26.7 million and nearly doubled net income to $5 million. It also notes a large August equity offering that strengthened the balance sheet, which the market could view as supportive despite dilution.
⚪️ BlackRock Inc. Buys Shares of 950,761 Red Violet, Inc. — MarketBeat.
🤖 This is primarily an institutional ownership filing showing BlackRock initiated a large position in RDVT, along with a director purchase. Because it is a backward-looking filing rather than a direct operating or financial catalyst, it is neutral for sentiment under the stated rules.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: Magnite is an advertising technology company that provides a sell-side platform for digital advertising. Its software helps publishers and media owners manage and monetize ad inventory across channels like connected TV, video, mobile, and desktop, while also connecting them with advertisers and agencies.
- 🎯 Current $23.71 is 11% below 3yr high $26.52 · ⏳ SMA200 $16.25 (current price $23.71 is above) · 💰 Market Cap $3.4B
- MGNI shows decent technicals supported by positive sentiment.

💎 Quality (Q): 50/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 62% (>20%); ROE 18% (>15%); Low LT D/E 0.37 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 0/20
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×3 ⚪️×2; showing 4 of 5).
✅ Magnite and ITN Expand Partnership to Introduce Agentic AI — GlobeNewswire.
🤖 Magnite announced an expanded partnership with ITN to add agentic AI capabilities to local linear advertising. The deal could improve activation and optimization for inventory, supporting Magnite’s ad-tech growth story.
✅ Magnite at Bank of America 2026 media conference: ctv strength, DOJ upside — Investing.com.
🤖 This conference transcript highlighted accelerating CTV growth and raised EBITDA margin guidance, both favorable for Magnite. It also pointed to potential long-term upside from the DOJ case against Google.
⚪️ WINTON GROUP Ltd Buys New Position in Magnite, Inc. $MGNI — MarketBeat.
🤖 This is a routine institutional filing about WINTON GROUP initiating a position in Magnite. It is backward-looking ownership disclosure and does not by itself indicate a business or earnings catalyst.
⚪️ Man Group plc Takes $1.01 Million Position in Magnite, Inc. $MGNI — MarketBeat.
🤖 This article reports a new institutional position in Magnite, which is a routine ownership disclosure. It does not include a new operational catalyst, guidance change, or analyst action.
🍭 Bonus (B): 10/10 — Computer Programming & Data Processing (Technology sector)

🏢 What they do: LTC Properties, Inc. is a real estate investment trust (REIT) focused on senior housing and healthcare properties in the United States. It invests in and leases properties such as skilled nursing facilities, assisted living communities, and memory care facilities to healthcare operators.
- 🎯 At/above 3yr high $43.46 (current $43.46) · ⏳ SMA200 $38.18 (current price $43.46 is above) · 💰 Market Cap $2.3B
- LTC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Base breakout (range: 9.2%); Low drawdown (12.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 75% (>20%); Revenue growth 64% (>15%).
⏰ Entry (E): 3/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 69 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ LTC Properties stock hits 52-week high at 43.04 USD — Investing.com.
🤖 LTC Properties reached a new 52-week high, supported by stronger-than-expected adjusted EPS and positive analyst actions. Deutsche Bank upgraded the stock to Buy with a $55 target, while RBC upgraded it to Outperform with a $45 target.
✅ Huntington Begins Coverage on LTC Properties (NYSE:LTC) — MarketBeat.
🤖 Huntington initiated coverage with an Outperform rating and a $47 price target, implying upside from the reported share price. The article also cited LTC’s quarterly EPS beat and broad Moderate Buy analyst consensus.
✅ LTC (LTC) Completed a $200M Senior-Housing Acquisition. Can ... — Yahoo Finance.
🤖 LTC completed a $200 million acquisition of four Minnesota senior-housing communities comprising 453 units. The transaction expands its senior-housing operating portfolio and supports the company’s SHOP-focused growth strategy.
🍭 Bonus (B): 0/10 — REITs